What is the 13F Pro Quality Score for MRK?

13F Pro ranks Merck & Co., Inc. (MRK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MRK's current score at https://13fpro.ai/research/MRK (free sign-up required for the full ranking).

Where does 13F Pro source MRK data?

All Merck & Co., Inc. fundamentals and ownership data come directly from SEC EDGAR. Merck & Co., Inc. files with the SEC under CIK 310158. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MRK in?

Merck & Co., Inc. (MRK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MRK research updated on 13F Pro?

MRK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Merck & Co., Inc.(MRK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 310158 MRK stock profile & AI dashboard →

13F Pro Quality Score

70.9/100

Rank #284 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

43.2/100

Profitability

71.9/100

Balance Sheet

82.1/100

Earnings Quality

77.7/100

Free Cash Flow

78.9/100

Institutional Flow

52.3/100

Revenue Scale

98.0/100

Dilution Risk

51.2/100

MRK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Merck & Co., Inc. (MRK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRK at 70.9/100 on a 32-signal composite quality model, placing it at rank #284 of 2,879 stocks — the top 10% of the AI-ranked universe. MRK scores in the top quartile across revenue scale (98.0), balance sheet strength (82.1), free cash flow (78.9). Based on the latest XBRL financial filings (Q1 2026), Merck & Co., Inc. reports quarterly revenue of $16.3B, net income of $-4.2B, free cash flow of $2.9B. MRK trades on the NYSE exchange and files with the SEC under CIK 310158. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Merck & Co., Inc. directly from SEC EDGAR. Merck & Co., Inc.'s 13F Pro composite quality score has ranged between 41 and 82 since 2021, currently 70.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Merck & Co., Inc.

Quirks, history, and lore behind MRK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on the NYSE · headquartered in New Jersey.
2
The Numbers
Annual revenue around $60 billion, with an R&D budget that rivals the GDP of a small nation — over $13 billion a year spent hunting for the next blockbuster drug.
3
The History
Traces its American roots to 1891, when a German chemist set up a chemical shop in New York; its parent company was actually seized as enemy property during World War I.
4
The Secret
It spun off its consumer health brands into a separate company in 2021, doubling down on prescription drugs and vaccines as its entire reason for being.
5
The Lore
Its antiviral pill Lagevrio and its cancer immunotherapy rival made it a household name during two of the biggest medical crises in recent memory — one viral, one oncological.
6
The Giveaway
The maker of Keytruda — the world's best-selling cancer drug — and the HPV vaccine Gardasil, this pharma giant shares a name with a German company it hasn't been related to in over a century.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$16.3B

Net Income

Q1 2026

$-4.2B

Free Cash Flow

Q1 2026

$2.9B

D/E Ratio

Q1 2026

1.07

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.3% YoY

$65.01BFY 2025

FY19 $39.12BFY23 $60.12BFY24 $64.17BFY25 $65.01B

Net Income

+6.6% YoY

$18.25BFY 2025

FY19 $9.84BFY23 $365.0MFY24 $17.12BFY25 $18.25B

EPS (Diluted)

+8.0% YoY

$7.28FY 2025

FY19 $3.81FY23 $0.14FY24 $6.74FY25 $7.28

Total Assets

+16.9% YoY

$136.87BFY 2025

FY19 $84.40BFY23 $106.67BFY24 $117.11BFY25 $136.87B

Total Debt

+32.9% YoY

$49.30BFY 2025

FY19 $26.30BFY23 $35.10BFY24 $37.10BFY25 $49.30B

Op. Cash Flow

-23.3% YoY

$16.47BFY 2025

FY19 $13.44BFY23 $13.01BFY24 $21.47BFY25 $16.47B

Metric	FY 2025	FY 2024	FY 2023	FY 2019	FY 2017	FY 2014
Revenue	$65.01B +1.3%	$64.17B +6.7%	$60.12B +53.7%	$39.12B -2.5%	$40.12B -5.0%	$42.24B
Net Income	$18.25B +6.6%	$17.12B +4589.6%	$365.0M -96.3%	$9.84B +311.2%	$2.39B -79.9%	$11.92B
EPS (Diluted)	$7.28 +8.0%	$6.74 +4714.3%	$0.14 -96.3%	$3.81 +337.9%	$0.87 -78.6%	$4.07
Total Assets	$136.87B +16.9%	$117.11B +9.8%	$106.67B +26.4%	$84.40B -4.0%	$87.87B -10.6%	$98.33B
Total Debt	$49.30B +32.9%	$37.10B +5.7%	$35.10B +33.5%	$26.30B -4.0%	$27.41B +22.3%	$22.40B
Operating Cash Flow	$16.47B -23.3%	$21.47B +65.1%	$13.01B -3.2%	$13.44B +108.3%	$6.45B -19.3%	$7.99B

Get alerted when MRK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Merck & Co., Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MRK on your watchlist

Track score changes the day Merck & Co., Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MRK a good stock to buy?

13F Pro's AI-powered analysis of Merck & Co., Inc. (MRK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRK are available on the MRK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MRK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Merck & Co., Inc.'s investment landscape.